Bank of New York Mellon’s Capricor Therapeutics CAPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.9M | Buy |
161,767
+31,037
| +24% | +$941K | ﹤0.01% | 2585 |
|
|
2026
Q1 | $3.97M | Buy |
130,730
+12,366
| +10% | +$329K | ﹤0.01% | 2443 |
|
|
2025
Q4 | $3.42M | Buy |
118,364
+23,694
| +25% | +$309K | ﹤0.01% | 2533 |
|
|
2025
Q3 | $683K | Buy |
94,670
+4,317
| +5% | +$31.8K | ﹤0.01% | 3424 |
|
|
2025
Q2 | $897K | Buy |
90,353
+2,633
| +3% | +$27.8K | ﹤0.01% | 3189 |
|
|
2025
Q1 | $832K | Buy |
87,720
+3,693
| +4% | +$51.3K | ﹤0.01% | 3166 |
|
|
2024
Q4 | $1.16M | Buy |
84,027
+20,638
| +33% | +$362K | ﹤0.01% | 3059 |
|
|
2024
Q3 | $964K | Sell |
63,389
-16,393
| -21% | -$81.1K | ﹤0.01% | 3155 |
|
|
2024
Q2 | $381K | Buy |
79,782
+9,040
| +13% | +$50.4K | ﹤0.01% | 3709 |
|
|
2024
Q1 | $480K | Sell |
70,742
-14,017
| -17% | -$67.8K | ﹤0.01% | 3549 |
|
|
2023
Q4 | $414K | Buy |
84,759
+412
| +0.5% | +$1.34K | ﹤0.01% | 3658 |
|
|
2023
Q3 | $288K | Sell |
84,347
-197
| -0.2% | -$1.11K | ﹤0.01% | 3813 |
|
|
2023
Q2 | $404K | Sell |
84,544
-53
| -0.1% | -$233 | ﹤0.01% | 3704 |
|
|
2023
Q1 | $357K | Hold |
84,597
| – | – | ﹤0.01% | 3670 |
|
|
2022
Q4 | $327K | Sell |
84,597
-59
| -0.1% | -$282 | ﹤0.01% | 3758 |
|
|
2022
Q3 | $508K | Hold |
84,656
| – | – | ﹤0.01% | 3554 |
|
|
2022
Q2 | $296K | Sell |
84,656
-719
| -0.8% | -$2.55K | ﹤0.01% | 3885 |
|
|
2022
Q1 | $293K | Hold |
85,375
| – | – | ﹤0.01% | 4028 |
|
|
2021
Q4 | $250K | Hold |
85,375
| – | – | ﹤0.01% | 4172 |
|
|
2021
Q3 | $343K | Hold |
85,375
| – | – | ﹤0.01% | 3988 |
|
|
2021
Q2 | $438K | Sell |
85,375
-1,391
| -2% | -$5.89K | ﹤0.01% | 3830 |
|
|
2021
Q1 | $406K | Sell |
86,766
-2,483
| -3% | -$14.3K | ﹤0.01% | 3801 |
|
|
2020
Q4 | $306K | Buy |
89,249
+28,809
| +48% | +$125K | ﹤0.01% | 3823 |
|
|
2020
Q3 | $317K | Buy |
+60,440
| New | +$352K | ﹤0.01% | 3702 |
|
|
2019
Q2 | – | Sell |
-2,430
| Closed | -$11K | – | 4217 |
|
|
2019
Q1 | $11K | Sell |
2,430
-80
| -3% | -$412 | ﹤0.01% | 4192 |
|
|
2018
Q4 | $10K | Hold |
2,510
| – | – | ﹤0.01% | 4195 |
|
|
2018
Q3 | $26K | Hold |
2,510
| – | – | ﹤0.01% | 4193 |
|
|
2018
Q2 | $34K | Sell |
2,510
-166
| -6% | -$2.26K | ﹤0.01% | 4133 |
|
|
2018
Q1 | $36K | Sell |
2,676
-68
| -2% | -$1.18K | ﹤0.01% | 4213 |
|
|
2017
Q4 | $44K | Buy |
+2,744
| New | +$59.4K | ﹤0.01% | 4218 |
|
|
2017
Q2 | – | Sell |
-1,496
| Closed | -$51K | – | 4302 |
|
|
2017
Q1 | $51K | Buy |
+1,496
| New | +$41.5K | ﹤0.01% | 4133 |
|
Other funds holding CAPR
MAP
PC
BDF
OC
GT
HSA
Bank of New York Mellon's CAPR Position: Q2 2026 in Review
Bank of New York Mellon increased its Capricor Therapeutics (CAPR) stake by 24% in Q2 2026, buying an estimated $941K and bringing the position to 161,767 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2585.
Bank of New York Mellon first reported a position in CAPR in Q1 2017 and has held it in 31 quarters since. The position peaked at $3.97M in Q1 2026. 55 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.
- Bank of New York Mellon held 161,767 shares of Capricor Therapeutics worth $3.9M as of Q2 2026.
- Bank of New York Mellon bought 31,037 Capricor Therapeutics shares in Q2 2026, an estimated $941K.
- Capricor Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2585 holding.
- Bank of New York Mellon first reported a position in Capricor Therapeutics in Q1 2017 and has held it in 31 quarters since.
- Bank of New York Mellon's Capricor Therapeutics position peaked at $3.97M in Q1 2026.
- 55 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.